Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01885585
NCT01885585
Completed
Not Applicable

Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention

Bristol-Myers Squibb1 site in 1 country100 target enrollmentJuly 2014
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsVenous Thromboembolism
InterventionsApixaban
DrugsApixaban

Overview

Phase
Not Applicable
Intervention
Apixaban
Conditions
Venous Thromboembolism
Sponsor
Bristol-Myers Squibb
Enrollment
100
Locations
1
Primary Endpoint
Number of Adverse Events (AEs) and serious AEs
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSitesSimilar Trials

Overview

Brief Summary

The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the safety and effectiveness information about Eliquis in general practice

Registry
clinicaltrials.gov
Start Date
July 2014
End Date
May 2015
Last Updated
10 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Signed data release
  • •Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty

Exclusion Criteria

  • •Being treated for an indication not approved for the use of Eliquis® in Korea
  • •Is contraindicated for the use of Eliquis® as described in the Korean label

Arms & Interventions

Patients with risk of VTE

Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release

Intervention: Apixaban

Outcomes

Primary Outcomes

Number of Adverse Events (AEs) and serious AEs

Time Frame: Up to 30 days after last study drug dose

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In KoreaDiabetes Mellitus Type 2
NCT02090673AstraZeneca1,711
Completed
Not Applicable
Eliquis Regulatory Post Marketing SurveillanceNonValvular Atrial Fibrillation
NCT01885598Bristol-Myers Squibb3,335
Completed
Not Applicable
ABF Tourette's Disorder Post Marketing Surveillance StudyTourette's Disorder
NCT01795105Korea Otsuka Pharmaceutical Co., Ltd.692
Active, not recruiting
Not Applicable
Iclusig PMS in CML or Ph+ALL PatientsChronic Myeloid LeukemiaPhiladelphia Chromosome-positive Acute Lymphoblastic Leukemia
NCT03709017Korea Otsuka Pharmaceutical Co., Ltd.50
Completed
Not Applicable
Abilify Maintena PMS in Schizophrenia Patients or Bipolar 1 DisorderSchizophreniaBipolar 1 Disorder
NCT03386851Korea Otsuka Pharmaceutical Co., Ltd.1,030